Immunotherapies have revolutionized cancer treatment approaches. Because not all patients respond positively to immune therapeutic agents, it represents a challenge for scientists who strive to understand the mechanisms behind such resistance. In-depth exploration of tumor biology, using novel technologies such as omics science, can help decode the role of the tumor immune microenvironment (TIME) in producing a response to the immune blockade strategies. It can also help to identify biomarkers for patient stratification and personalized treatment. This review aims to explore these new models and highlight their possible pivotal role in changing clinical practice.
Immunotherapy and Cancer: The Multi-Omics Perspective
Clelia Donisi
Primo
Data Curation
;Andrea PrettaSecondo
Writing – Review & Editing
;Valeria Pusceddu;Pina Ziranu;Marco Puzzoni;Elena MassaSupervision
;Clelia Madeddu and Mario Scartozzi
2024-01-01
Abstract
Immunotherapies have revolutionized cancer treatment approaches. Because not all patients respond positively to immune therapeutic agents, it represents a challenge for scientists who strive to understand the mechanisms behind such resistance. In-depth exploration of tumor biology, using novel technologies such as omics science, can help decode the role of the tumor immune microenvironment (TIME) in producing a response to the immune blockade strategies. It can also help to identify biomarkers for patient stratification and personalized treatment. This review aims to explore these new models and highlight their possible pivotal role in changing clinical practice.File | Dimensione | Formato | |
---|---|---|---|
Donisi et Al.pdf
accesso aperto
Descrizione: Articolo principale
Tipologia:
versione editoriale (VoR)
Dimensione
288.49 kB
Formato
Adobe PDF
|
288.49 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.